Elaine K. Perry

Elaine K. Perry's AcademicInfluence.com Rankings

Elaine K. Perry

Philosophy

#4518

World Rank

#7067

Historical Rank

Logic

#1952

World Rank

#2832

Historical Rank

philosophy Degrees

Elaine K. Perry

Biology

#5913

World Rank

#8511

Historical Rank

Neuroscience

#690

World Rank

#722

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Elaine K. Perry Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Elaine K. Perry's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and management of dementia with Lewy bodies (2005) (3346)
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. (1996) (2280)
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) (1996) (2138)
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. (1978) (2024)
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors (2008) (1033)
Acetylcholine in mind: a neurotransmitter correlate of consciousness? (1999) (753)
Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue (1977) (721)
Neuroleptic sensitivity in patients with senile dementia of Lewy body type. (1992) (641)
Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly (1990) (594)
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. (1985) (571)
The cholinergic hypothesis--ten years on. (1986) (568)
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. (1997) (546)
CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE (1978) (500)
Report of the second dementia with Lewy body international workshop (1999) (484)
Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases (1983) (456)
Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies (2000) (451)
ALUMINOSILICATES AND SENILE PLAQUE FORMATION IN ALZHEIMER'S DISEASE (1986) (429)
Operational criteria for senile dementia of Lewy body type (SDLT) (1992) (429)
Autism as a disorder of neural information processing: directions for research and targets for therapy* (2004) (417)
Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. (2002) (399)
Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology (1995) (391)
Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial (2003) (386)
Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations (2005) (380)
Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. (2001) (347)
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. (1999) (326)
Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil (2003) (317)
Differences in neuropathologic characteristics across the Lewy body dementia spectrum (2006) (308)
Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides (1984) (305)
Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. (1999) (304)
Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness (1995) (283)
Medicinal Plants and Alzheimer's Disease: from Ethnobotany to Phytotherapy ** (1999) (274)
Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease (1981) (260)
Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia (1999) (257)
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. (1994) (256)
Decreased Imipramine Binding in the Brains of Patients with Depressive Illness (1983) (254)
Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of meynert in Alzheimer's disease (1982) (245)
The cholinergic system in old age and Alzheimer's disease. (1980) (236)
Coenzyme a-acetylating enzymes in Alzheimer's disease: Possible cholinergic ‘compartment’ of pyruvate dehydrogenase (1980) (233)
Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm) (2002) (233)
Nicotinic receptor abnormalities in the cerebellar cortex in autism. (2002) (232)
Nicotinic receptor abnormalities in Alzheimer’s disease (2001) (230)
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs (2003) (226)
Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes (1981) (218)
Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: Selective loss of the intermediate (10S) form (1983) (216)
CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. (2000) (212)
Dementia with Lewy bodies. (2007) (212)
Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia: Similarity to Parkinson's and Distinction from Alzheimer Disease (1993) (212)
Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia (1990) (203)
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. (2005) (197)
Chronic nicotine treatment reduces β‐amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw) (2002) (197)
Aromatherapy in the Management of Psychiatric Disorders (2006) (195)
α4 but Not α3 and α7 Nicotinic Acetylcholine Receptor Subunits Are Lost from the Temporal Cortex in Alzheimer's Disease (1999) (190)
Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. (1987) (181)
Modulation of Mood and Cognitive Performance Following Acute Administration of Single Doses of Melissa Officinalis (Lemon Balm) with Human CNS Nicotinic and Muscarinic Receptor-Binding Properties (2003) (180)
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia (2001) (179)
Nicotinic receptors in human brain: topography and pathology (2000) (179)
Molecular Forms of Acetylcholinesterase and Butyrylcholinesterase in the Aged Human Central Nervous System (1986) (176)
Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease (1981) (174)
A cholinergic connection between normal aging and senile dementia in the human hippocampus (1977) (172)
Convergent cholinergic activities in aging and Alzheimer's disease (1992) (170)
Salvia lavandulaefolia (Spanish Sage) enhances memory in healthy young volunteers (2003) (169)
EUROPEAN HERBS WITH CHOLINERGIC ACTIVITIES: POTENTIAL IN DEMENTIA THERAPY (1996) (167)
Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication (2000) (163)
Delusions associated with elevated muscarinic binding in dementia with Lewy bodies (2000) (160)
Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology (2009) (160)
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial (2000) (157)
Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease (1991) (157)
Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology (2012) (154)
Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers (2005) (152)
Altered neurogenesis in Alzheimer's disease. (2006) (151)
Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. (1997) (151)
The Role of Phytochemicals in the Treatment and Prevention of Dementia (2011) (151)
Monoamine metabolism in senile dementia of Alzheimer type (1983) (151)
Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380 (2004) (149)
Angiotensin Converting Enzyme in Alzheimer's Disease: Increased Activity in Caudate Nucleus and Cortical Areas (1982) (148)
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. (1994) (146)
Cholinergic Receptors in Cognitive Disorders (1986) (146)
An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers (2008) (145)
Molecular analysis of nicotinic receptor expression in autism. (2004) (143)
Alzheimer's disease is associated with a selective increase in α7 nicotinic acetylcholine receptor immunoreactivity in astrocytes (2003) (143)
Distribution of Nicotinic Receptors in the Human Hippocampus and Thalamus (1994) (142)
Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use (1998) (138)
Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies (2007) (133)
Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types (1990) (132)
Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. (2004) (132)
Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice (2004) (131)
5-HT receptor binding in post-mortem brain from patients with affective disorder. (1987) (130)
Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type (1984) (128)
Medicinal Plants and Dementia Therapy: Herbal Hopes for Brain Aging? (2011) (128)
The influence of agonal status on some neurochemical activities of postmortem human brain tissue (1982) (124)
Cortical cholinergic dysfunction after human head injury. (1998) (121)
Dementia with Lewy Bodies. A Distinct Non‐Alzheimer Dementia Syndrome? (1998) (120)
Lewy bodies and response to tacrine in Alzheimer's disease (1994) (119)
Neuropeptides in Alzheimer's disease, depression and schizophrenia A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex (1981) (118)
Oxidative Damage to Proteins, Lipids, and DNA in Cortical Brain Regions from Patients with Dementia with Lewy Bodies (1998) (113)
Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. (1998) (113)
A Double-Blind Placebo-Controlled Randomized Trial of Melissa officinalis Oil and Donepezil for the Treatment of Agitation in Alzheimer’s Disease (2011) (111)
Nerve cell loss in the thalamus in Alzheimer's disease and Parkinson's disease. (1991) (109)
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia (2003) (107)
CORTICAL CHOLINERGIC DEFICIT IN MENTALLY IMPAIRED PARKINSONIAN PATIENTS (1983) (106)
Histochemical observations on cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients. (1980) (105)
Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease. (1980) (105)
CLINICALLY AND NEUROPATHOLOGICALLY DISTINCT FORM OF DEMENTIA IN THE ELDERLY (1989) (104)
Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. (2002) (104)
Depletion of MAP2 expression and laminar cytoarchitectonic changes in dorsolateral prefrontal cortex in adult autistic individuals (2004) (104)
Cholinergic and Dopaminergic Activities in Senile Dementia of Lewy Body Type (1990) (104)
Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology (1999) (103)
Intralaminar Neurochemical Distributions in Human Midtemporal Cortex: Comparison Between Alzheimer's Disease and the Normal (1984) (95)
Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases (1991) (95)
Human brain neurochemistry - some postmortem problems. (1983) (94)
[3H]MK-801 binding to the NMDA receptor complex, and its modulation in human frontal cortex during development and aging (1992) (92)
The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human spinal cord (1991) (85)
Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum (2002) (85)
Quantification and Characterisation of Fluctuating Cognition in Dementia with Lewy Bodies and Alzheimer’s Disease (2000) (84)
Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. (1994) (80)
Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: Comparisons with Parkinson's disease (1984) (79)
Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus (2003) (78)
Nicotinic receptor distribution in the human thalamus: autoradiographical localization of [3H]nicotine and [125I]α-bungarotoxin binding (1997) (78)
Clinical neurochemistry: developments in dementia research based on brain bank material (1998) (78)
Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro (1988) (77)
Regional patterns of cholinergic and glutamate activity in the developing and aging human brain. (1993) (76)
Postmortem Neurochemical Studies in Depression (1986) (76)
Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine (1999) (75)
Hippocampal Free Amino Acids in Alzheimer's Disease (1980) (75)
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. (1996) (75)
Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. (2004) (73)
Selective Nicotinic Receptor Consequences in APPSWE Transgenic Mice (2002) (72)
Cholinergic systems in progressive supranuclear palsy. (2004) (71)
Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy Bodies (2004) (71)
Neuronal nicotinic acetylcholine receptor subunits in autism: an immunohistochemical investigation in the thalamus (2005) (71)
Nicotinic receptor subtypes in human brain related to aging and dementia. (2001) (70)
α4β2 nicotinic receptor status in Alzheimer’s disease using 123I-5IA-85380 single-photon-emission computed tomography (2006) (70)
Muscarinic Cholinergic Receptor Subtypes in Hippocampus in Human Cognitive Disorders (1988) (70)
Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimer’s Disease (2015) (69)
Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease (2003) (69)
Medicinal Plant Extracts for the Treatment of Dementia (2000) (68)
Distribution of histamine H3‐receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases (1999) (68)
Comparison of methods for determination of total antioxidant status: application to analysis of medicinal plant essential oils (1998) (67)
Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain (2002) (67)
Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies (2007) (65)
Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson’s disease (1998) (65)
Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types (2000) (63)
Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain — A preliminary study in Alzheimer's disease (1987) (62)
Monoaminergic activities in Lewy Body dementia: Relation to hallucinosis and extrapyramidal features (1993) (62)
Dementia: the neurochemical basis of putative transmitter orientated therapy. (1991) (62)
The role of the cholinergic system in the development of the human cerebellum. (1995) (60)
The current status of the cortical cholinergic system in Alzheimer's disease and Parkinson's disease. (1986) (60)
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease (1995) (58)
Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. (1999) (56)
Recovery and measurement of specific RNA species from postmortem brain tissue: a general reduction in Alzheimer's disease detected by molecular hybridization. (1986) (55)
Cerebral Cholinergic Activity Is Related to the Incidence of Visual Hallucinations in Senile Dementia of Lewy Body Type (1990) (55)
Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology (2004) (55)
Selective changes in nicotinic acetylcholine receptor subtypes related to tobacco smoking: an immunohistochemical study (2004) (54)
Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression (1983) (54)
In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia (2006) (54)
Biochemical assay of Alzheimer's disease--associated protein(s) in human brain tissue. A clinical study. (1990) (53)
Expression of the α3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease (1998) (52)
Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies (2005) (52)
Parameters of cholinergic neurotransmission in the thalamus in Parkinson's disease and Alzheimer's disease (1990) (52)
Nicotinic α4β2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations (2008) (51)
Autoradiographic distribution of [3H]nicotine binding in human cortex: Relative abundance in subicular complex (1992) (50)
Visual hallucinations are associated with lower αbungarotoxin binding in dementia with Lewy bodies (2001) (50)
Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias. (1996) (50)
A study of the serotonin transporter in the prefrontal cortex in late‐life depression and Alzheimer's disease with and without depression (2006) (49)
Sodium dependent d-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases (1987) (48)
Synaptic Proteins and Choline Acetyltransferase Loss in Visual Cortex in Dementia With Lewy Bodies (2013) (47)
The effect of drug treatment on neurogenesis in Parkinson's disease (2011) (47)
Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease (2000) (46)
Molecular Forms of Acetylcholinesterase and Butyrylcholinesterase in Human Plasma and Cerebrospinal Fluid (1987) (46)
Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [125I]α-conotoxinMII in the striatum and thalamus (2005) (45)
Evidence for the early prenatal development of cortical cholinergic afferents from the nucleus of Meynert in the human foetus (1985) (45)
Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression (1990) (44)
CNS Nicotinic Receptors (1994) (43)
The substantia innominata and adjacent regions in the human brain: histochemical and biochemical observations. (1984) (43)
Neocortical Cholinergic Enzyme and Receptor Activities in the Human Fetal Brain (1986) (43)
An autoradiographic analysis of serotonin receptors in human temporal cortex: Changes in Alzheimer-type dementia (1988) (42)
Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment (2005) (41)
Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism (2006) (40)
Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson’s Disease Dementia (2008) (40)
Regional distribution of muscarinic and nicotinic cholinergic receptor binding activities in the human brain. (1989) (40)
SENILE DEMENTIA OF LEWY BODY TYPE AND SPECTRUM OF LEWY BODY DISEASE (1989) (38)
Memory following cholinergic (NBM) and noradrenergic (DNAB) lesions made singly or in combination: Potentiation of disruption by scopolamine (1990) (38)
Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex (2002) (38)
New horizons in the neuroscience of consciousness (2010) (37)
Comparison of the binding of nicotinic agonists to receptors from human and rat cerebral cortex and from chick brain (α4β2 ) transfected into mouse fibroblasts with ion channel activity (1994) (37)
Attenuation of Aβ deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking (2005) (37)
Increases in muscarinic stimulated hydrolysis of inositol phospholipids in rat hippocampus following cholinergic deafferentation are not parallelled by alterations in cholinergic receptor density (1989) (36)
Neurochemistry of consciousness: cholinergic pathologies in the human brain. (2004) (36)
Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases. (1987) (36)
Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease (1985) (36)
Role of phytochemicals as nutraceuticals for cognitive functions affected in ageing (2020) (36)
Increased neural progenitors in vascular dementia (2011) (35)
Blood acetyl- and butyrylcholinesterases in senile dementia of Alzheimer type (1985) (35)
Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. (2007) (35)
Nerve Growth Factor and the Basal Forebrain Cholinergic System: A Link in the Etiopathology of Neurodegenerative Dementias? (1990) (35)
A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age. (2018) (35)
Lewy body dementia--clinical, pathological and neurochemical interconnections. (1997) (34)
Co-Localization of Aluminium and Silicon in Senile Plaques: Implications for the Neurochemical Pathology of Alzheimer’s Disease (1985) (33)
Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies (2010) (32)
Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies (2006) (32)
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems (2008) (31)
A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. (2002) (31)
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer’s disease (2009) (31)
Molecular Forms of Butyrylcholinesterase in the Human Neocortex During Development and Degeneration of the Cortical Cholinergic System (1987) (30)
Hippocampal nerve growth factor receptor immunoreactivity in patients with Alzheimer's and Parkinson's disease (1992) (29)
Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus (1993) (29)
Quantification and characterization of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. (2000) (29)
Dementia with Lewy Bodies: What is the neuropathological basis of dementia associated with Lewy bodies? (1996) (28)
Muscarinic acetylcholine receptor status in Alzheimer’s disease assessed using (R, R) 123I-QNB SPECT (2007) (28)
Neocortical concentrations of neuropeptides in senile dementia of the alzheimer and lewy body type: Comparison with parkinson's disease and severity correlations (1991) (28)
Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease: relation to changes in α-synuclein expression (2002) (28)
Cortical and subcortical pathology in Parkinson's disease: relationship to parkinsonian dementia. (1990) (27)
β‐Amyloidosis in Normal Aging and Transmitter Signaling in Human Temporal Lobe a (1996) (27)
Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer's disease and dementia with Lewy bodies. (2010) (27)
Properties and possible significance of substance P and insulin fibrils (1981) (27)
Gender differences in the phenotypic expression of Alzheimer's disease in Down's syndrome (Trisomy 21) (1994) (27)
Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. (2007) (26)
Visual hallucinations and the cholinergic system in dementia. (1990) (26)
Nicotine reduces the binding of [3H]MK-801 to brain membranes, but not via the stimulation of high-affinity nicotinic receptors (1990) (26)
The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human brainstem in relation to motor neuron disease (1992) (26)
Glutamate receptor binding in the human hippocampus and adjacent cortex during development and aging (1996) (26)
A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias (1999) (25)
Circadian variations in cholinergic enzymes and muscarinic receptor binding in human cerebral cortex (1977) (25)
The neuroscience of visual hallucinations (2015) (24)
New insights into the nature of senile (Alzheimer-type) plaques (1985) (24)
The K Variant of the Butyrylcholinesterase Gene Is Associated with Reduced Phosphorylation of Tau in Dementia Patients (2005) (24)
A review of neuropathological and neurochemical correlates of Alzheimer's disease. (1985) (24)
Autoradiographic comparison of the distribution of [3H]MK801 and [3H]CNQX in the human cerebellum during development and aging (1993) (24)
Transmitters in the Developing and Senescent Human Brain (1993) (23)
Age-associated decline in high-affinity nicotine binding in human brain frontal-cortex does not correlate with the changes in choline-acetyltransferase activity (1992) (23)
Recovery and measurement of RNA in Alzheimer's disease by molecular hybridisation. (1987) (23)
Neurogenic marker abnormalities in the hippocampus in dementia with Lewy bodies (2011) (23)
Effects of repeated anaesthesia on central cholinergic function in the rat cerebral cortex (2003) (22)
Neurochemistry of consciousness : neurotransmitters in mind (2002) (22)
Neurotransmitter Abnormalities in Vascular Dementia (2003) (22)
Distribution of nerve growth factor receptor immunoreactivity in the human hippocampus (1991) (22)
Use of herbal medicines: Pilot survey of UK users' views. (2019) (21)
Comparison of major cortical aminopeptidase activity in normal brain and brain from patients with Alzheimer's disease (1989) (21)
Involvement of α6/α3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [125I]-α-conotoxin MII binding in the thalamus and striatum. (2004) (21)
Distribution of [3H]MK801 binding in the normal aged human hippocampus (1989) (21)
Partial loss of parvalbumin‐containing hippocampal interneurons in dementia with Lewy bodies (2011) (20)
Examination of Parameters Influencing [3H]MK‐801 Binding in Postmortem Human Cortex (1992) (20)
Abnormally Phosphorylated Tau Protein in Senile Dementia of Lewy Body Type and Alzheimer Disease: Evidence that the Disorders Are Distinct (1995) (20)
Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline (2007) (19)
Dementia with Lewy Bodies: Altered consciousness and transmitter signalling in Lewy body dementia (1996) (19)
The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer's disease and dementia with Lewy bodies (2006) (18)
Dreaming and hallucinations – Continuity or discontinuity? Perspectives from dementia with Lewy bodies (2011) (18)
Neurochemical pathology and therapeutic strategies in degenerative dementia (1993) (17)
Neurotransmitter mechanisms of dreaming: Implication of modulatory systems based on dream intensity (2000) (17)
Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies (2005) (17)
Subject Index Vol. 11, 2000 (2000) (16)
Chronic nicotine treatment reduces beta-amyloidosis (2002) (16)
Hippocampal p75 nerve growth factor receptor immunoreactivity in development, normal aging and senescence. (1993) (16)
Expression of the alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. (1998) (16)
HUMAN BRAIN TEMPERATURE AT NECROPSY: A GUIDE IN POST-MORTEM BIOCHEMISTRY (1977) (15)
New observations on the nature of senile plaque cores (1984) (15)
Upregulation of neuronal nicotinic receptor subunits α4, β2, and α7 in transgenic mice overexpressing human acetylcholinesterase (2002) (15)
Dementia in old age: identification of a clinically and pathologically distinct disease category. (1990) (14)
Alpha4 but not alpha3 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease (1999) (14)
Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study (2018) (14)
Comparison of Ca2+-activated proteinase enzyme and endogeneous inhibitor activity in brain tissue from normal and Alzheimer's disease cases (1991) (14)
Multiple substrates of late-onset dementia: implications for brain protection. (2001) (14)
Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity. (1994) (14)
Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase. (2002) (14)
Nicotinic ( 3 H nicotine) receptor binding in human brain: characterization and involvement in cholinergic neuropathology (1989) (13)
Beta-amyloidosis in normal aging and transmitter signaling in human temporal lobe. (1996) (13)
Some Observations and Speculations Concerning the Cholinergic System and Neuropeptides in Alzheimer's Disease (1983) (13)
Increased neural progenitors in individuals with cerebral small vessel disease (2012) (13)
Cholinergic Component of Cognitive Impairment in Dementia (1994) (13)
Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit (2007) (12)
Neuronal aging and its implications in human neurological pathology World Health Organization Technical Report Series No. 665, 1981. SFr. 6 (88 pages) ISBN 92 4 120665 9. (French and Spanish editions in preparation) (1982) (12)
Lewy body diseases (2002) (12)
Tautological tangles in neuropathologic criteria for dementias associated with Lewy bodies (1996) (12)
Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease (1983) (12)
Cholinergic phytochemicals: From magic to medicine (1997) (12)
Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti‐agitation properties: focus on ligand‐gated channels (2008) (11)
Modulatory effects of guanylylimidodiphosphate and Mg2+ on [3H]oxotremorine-M binding in normal and Alzheimer's disease parietal cortex: an index of muscarinic receptor-G-protein coupling (1989) (11)
Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients (2008) (11)
Involvement of Neuronal Nicotinic Receptors in Disease (2000) (10)
Alzheimer's Disease and Parkinson's Disease: Pathological and Biochemical Changes Associated with Dementia (1985) (10)
Alterations in nicotinic α4β2 receptor binding in vascular dementia using 123I-5IA-85380 SPECT: Comparison with regional cerebral blood flow (2011) (10)
Loss and recovery of acetylcholinesterase molecular forms in the fornix-lesioned rat hippocampus (1987) (10)
Evidence of a circadian fluctuation in neurotransmitter enzyme activities measured in autopsy human brain (1977) (10)
Comparison of aminopeptidase, dipeptidyl aminopeptidase and tripeptidyl aminopeptidase activities in brain tissue from normal and Alzheimer's disease cases (1990) (10)
Neurotransmitter Correlates of Neuropsychiatric Symptoms in Dementia with Lewy Bodies (2003) (10)
Cholinergic Component of Autism Spectrum Disorder (2010) (10)
Near Death Experiences: A New Algorithmic Approach to Verifying Consciousness Outside the Brain (2010) (9)
Post-mortem studies in affective disorder (1992) (9)
Cholinergic Neuropathology and Nicotinic Receptor Binding in the Human Brain (1988) (8)
Thalamic D 2 receptors in dementia with Lewy bodies, Parkinson’s disease, and Parkinson’s disease dementia (2007) (8)
Effect of flavonoids on protease activities in human skeletal muscle tissue in vitro. (1999) (8)
Neurochemical pathology of dementia with Lewy bodies (2006) (8)
Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. (2004) (8)
Distribution of neurofibrillary tangle formation and [3H]‐D‐aspartate receptor binding in the thalamus in the normal elderly brain, in Alzheimer's disease and in Parkinson's disease (1990) (7)
In vitro inhibition of human acetyl- and butyryl-cholinesterase by Narcissus poeticus L. (Amaryllidaceae) flower absolute (2008) (7)
Examination of Cholinergic and Neuropeptide Receptor Alterations in Senile Dementia of the Alzheimer’s Type (SDAT) (1986) (7)
13. Plants of the gods: Ethnic routes to altered consciousness (2002) (6)
Brain Biochemistry in Dementia of Alzheimer‑type (1981) (6)
Measurement of relative concentrations of rna in post mortem brains from senile dementia of the alzheimer type and controls (1985) (6)
Neuropathological and Neurochemical Correlates of Alzheimer‑type and Parkinsonian Dementia (1984) (6)
Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: Contrast with other dementias (2008) (6)
Melissa aromatherapy as safe and effective treatment (2003) (5)
Neurotransmitter and neuropeptide systems in Alzheimer-type dementia. (1982) (5)
Fimbria-fornix lesions in aged rats cause increased carbachol-stimulated phosphoinositide hydrolysis in the hippocampus, but no change in muscarinic receptor binding (1990) (5)
Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (2007) (5)
Neuroanatomical and Neurochemical Studies of the Autistic Brain: Current Thought and Future Directions (2006) (5)
Structural and Chemical Aspects of Cortical Pathology in Alzheimer’s Disease (1986) (4)
Acetylcholinesterase in Alzheimer's Disease (1983) (4)
Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's disease and Parkinson's disease cases (1999) (4)
Hypothesis linking plasticity, vulnerability and nerve growth factor to basal forebrain cholinergic neurons (1990) (4)
N-methyl-D-aspartate (NMDA) and non-NMDA binding sites in developing human frontal cortex (1993) (4)
Stage-Speci fi c Changes in Neurogenic and Glial Markers in Alzheimer ’ s Disease (2015) (4)
Thalamocortical dysfunction and complex visual hallucinations in brain disease – Are the primary disturbances in the cerebral cortex? (2004) (4)
Dynamin protein in stroke and vascular dementia (2014) (3)
Neurochemistry of Consciousness: Neurotransmitters in Mind. Advances in Consciousness Research (2002) (3)
Cholinergic pathology in dementia with Lewy bodies (2017) (3)
Cholinergic and gaba systems in dementia and normal old-age (1977) (3)
Dopamine metabolism in postmortem caudate-nucleus in neurodegenerative disorders (1994) (3)
The Ageing Brain and its Pathology (1982) (3)
Striatal dopaminergic loss without parkinsonism in a case of corticobasal degeneration (1997) (3)
Plants of the gods and shamanic journeys (2010) (2)
Biological correlates of dementia (1992) (2)
Neurochemical pathology in degenerative dementias (2001) (2)
The Nicotinic Cholinergic System and ß-Amyloidosis (1997) (2)
S.02.04 Lewy body disease: How are dementiawith Lewy bodies and Parkinson's disease dementia related? (2004) (2)
Increased Alzheimer pathology in Parkinson's disease is associated with chronic antimuscarinic drug treatment (2002) (2)
Neurochemical pathology of cholinergic systems in neurodegenerative and neurdevelopmental disorders (2006) (2)
Electron-microscopic demonstration of fibrillary forms of small peptides common to brain and gut (1981) (2)
Butyrylcholinesterase: Potential Importance for the Symptoms and Progression of Cognitive Decline in People with Dementia (2003) (2)
Neurochemical pathology of Parkinson’s disease dementia (2010) (2)
Effect of fimbria/fornix lesions on muscarinic and nicotinic receptor densities and muscarinic receptor efficacy in rat hippocampus (1989) (2)
Researching the Autism Spectrum: Biochemistry of autism: changes in serotonin, reelin and oxytocin (2011) (2)
Nerve growth factor receptor-like immunoreactivity in the human spinal cord. (1992) (2)
Neurotransmitters and diseases of the brain. (1991) (2)
Dementia with Lewy Bodies: Introduction (1996) (2)
Do multiple cortical–subcortical interactions support different aspects of consciousness? (2007) (2)
The effects of donepezil on nicotinic receptor status in dementia: a 123I-5IA-85380 SPECT study (2007) (2)
Still PADing along: Perception and attention remain key factors in understanding complex visual hallucinations (2005) (2)
Neurotensin immunoreactivity and choline acetyltransferase activity in the cerebral cortex in Parkinson's disease (1983) (1)
P1-435 Essential oils as potential treatment for agitation in severe dementia: Elucidation of the pharmacological mechanism of Melissa and Lavender oils (2006) (1)
Cholinergic pathology in Lewy body dementia (2006) (1)
The status of hippocampal cholinergic receptors in human cognitive disorders (1986) (1)
Existence in vitro of fibrillary aggregates of substance P, cholecystokinin octapeptide, somatostatin and related molecules (1981) (1)
Recovery and measurement of specific RNA species from postmortem brain tissue: a general reduction in Alzheimerʼs disease detected by molecular hybridization (1987) (1)
Cortical tau-protein and neurofibrillary tangles in lewy body dementia, alzheimers-disease, parkinsons-disease and controls (1994) (1)
Tobacco use is associated with attenuation of beta-amyloidosis in hippocampus and entorhinal cortex of normal elderly individuals (2002) (1)
Letter to the editor (1991) (1)
Neurochemical Pathology of Alzheimer's Disease - The Cholinergic Concept (1984) (1)
Transmitter Systems in Alzheimer's Disease (1983) (1)
Cholinergic therapy for autistic spectrum disorder (2012) (1)
[abstract] A Randomized controlled trial of aromatherapy for dementia (2003) (1)
Cholinergic therapy for autistic spectrum disorders: Review and case report (2012) (1)
Cerebral emboli predict cognitive decline in the common dementias (2008) (1)
P.3.008 Dopaminergic and nicotinic interactions in the human striatum in dementia with lewy bodies, chronic schizophrenia and Parkinson's disease (1996) (1)
Dementia with Lewy Bodies: Biographical note on F. H. Lewy (1996) (1)
Butyrylcholinesterase: Impact on symptoms and progression of cognitive impairment in dementia (2004) (1)
Autism: What about old age? (2009) (1)
Hallucinations and Imagination (2020) (1)
Unfolding the nature of senile plaque amyloid (1986) (1)
Neurotransmitter Changes in Alzheimer's Disease: Relationships to Symptoms and Neuropathology (2002) (1)
GASTRIN/CCK IMMUNOREACTIVITY IN HUMAN CEREBRAL CORTICAL GREY AND WHITE MATTER (1981) (1)
Monoaminergic Function in Postmortem Brain in Depression (1982) (1)
Neurodegenerative Changes in Aging and Dementia: A Comparison of Alzheimer and Lewy Body Type Pathology (1992) (1)
Dementia with Lewy bodies: A disorder of consciousness? (2002) (1)
Expression of nicotinic achetylcholine receptor subunits in ache-transgenic mice (2000) (1)
Cholinergic component of vascular dementia (1999) (1)
On neuronal ill health (1994) (1)
Molecular Basis of Cholinergic Changes in Autism Spectrum Disorders and Relevance for Treatment Interventions (2015) (1)
Phytopharmaceuticals for Dementia Therapy (2009) (1)
Neuropathology of the cholinergic system in the human brain (1984) (1)
Comparison of Ca 2+ -activated proteinase enzyme and inhibitor levels in cerebral cortex from normal and Alzheimer disease cases (1989) (1)
Dementia with Lewy Bodies: Résumé of treatment workshop sessions (1996) (1)
Cholinergic controversies. (1991) (1)
D2 receptors in thalamus and cortex in Parkinson's disease dementia (PDD), Parkinson's disease (PD) and dementia with Lewy bodies (DLB) (2006) (1)
Changes in human brain nicotine receptors in dementia, development and aging: association with neuropathology and plasticity (1995) (0)
Implications of Neuropathological and Neurochemical Abnormalities in Alzheimer's Disease (1984) (0)
Nicotine treatment attenuates beta-amyloidosis in brain of transgenic APPsw mice (2002) (0)
I-5 IA-85380 SPECT : Comparison with regional cerebral lood flow (2010) (0)
Cholinergic components of cognitive and neuropsychiatric features of human brain aging (2000) (0)
Contents, Vol. 144, 1992 (1992) (0)
P2-226: Association of proteasome subunit expression with reduced proteolytic activity in dementia with Lewy bodies and Parkinson's disease dementia (2008) (0)
Subject Index, Vol. 144, 1992 (1992) (0)
640 Consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) (1996) (0)
Reply to Hölscher (1999) (0)
Dementia with Lewy Bodies: Group photograph (1996) (0)
IA-85380 SPECT 123 status in dementia : a The effects of donepezil on nicotinic receptor (2008) (0)
Future directions for research (2014) (0)
P2-322 Measurement of the α4β2 nicotinic receptor in vivo in Alzheimer’s disease with 123I-5ia-85380 SPECT (2006) (0)
Decreased levels of amyloid beta peptide in the brains of smokers (2005) (0)
Contents, Vol. 147, 1993 (1993) (0)
The Management of Psychotic Symptoms in Dementia with Lewy Bodies (dlb) (1996) (0)
Distribution of Nicotinic Receptors in the CNS (2020) (0)
Structure and distribution of nicotinic receptors in human brain (1995) (0)
1. Neurotransmitter networks (2002) (0)
Neurochemical pathological studies of autism (2006) (0)
IC-P-059 Measurement of the α4β2 nicotinic receptor in vivo in Alzheimer’s disease with 123I-5IA-85380 SPECT (2006) (0)
Cholinergic and Monoaminergic Correlates of Clinical Symptoms in Dementia with Lewy Bodies (2002) (0)
Dementia with Lewy Bodies: Guidelines for the selection of cortical areas for the evaluation of Lewy body distribution and proposed diagnostic rating protocol (1996) (0)
[meeting abstract] Decreased levels of amyloid-beta peptide in the entorhinal cortex of normal elderly individuals associated with tobacco smoking (2005) (0)
New perspectives on sleep disturbances and memory in human pathological and psychopharmacological states (2005) (0)
Management of Noncognitive Symptoms in Dementia with Lewy Bodies (1998) (0)
Subject Index, Vol. 147, 1993 (1993) (0)
Aluminosilicates and senile plaque formation in Alzheimerʼs disease (1987) (0)
[abstract] Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) [I-123]-QNB SPECT (2006) (0)
Dementia with Lewy Bodies: Consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) (1996) (0)
Recovery and measurement of RNA in Alzheimerʼs disease by molecular hybridization (1988) (0)
Histochemistry of Brain Cholinesterases in Normal Old Age and Alzheimer's disease (1980) (0)
The response of human nicotinic receptors in the hippocampus and cerebellum to cigarette smoking: Possible neuroprotective associates (1995) (0)
Altered tau processing: its role in development of dementia in Alzheimer's disease and Lewy body disease (1996) (0)
Loss of synaptic proteins and choline acetyltransferase in primary and secondary visual cortex in dementia with Lewy bodies (2008) (0)
From James Parkinson to Friederich Lewy: leaving landmarks for further research journeys. (2003) (0)
Association of proteasome subunit expression with reduced proteolytic activity in dementia with Lewy bodies and Parkinson's disease dementia (2008) (0)
Neurochemical pathology of Parkinson’s disease dementia and dementia with Lewy bodies (2015) (0)
Dementia with Lewy Bodies: Plate section (1996) (0)
Amyloid and Alzheimer's disease: A question of specificity (1989) (0)
Contents Vol. 19, 2005 (2005) (0)
Cognitive and mood effects of acute administration of a Melissa officinalis with human CNS cholinergic receptor binding properties (2002) (0)
Clinical, pathological and neurochemical characteristics of Lewy body dementia (1995) (0)
Nerve growth factor receptor-positive fibre pathways in the human neocortex. (1990) (0)
Neurogenic marker alterations in the hippocampus in relation to cholinergic therapy in Lewy Body dementia (2014) (0)
Optimal brain banking: The Newcastle experience (1996) (0)
Subject Index Vol. 19, 2005 (2005) (0)
Psychopharmacology of aging edited by Carl Eisdorfer and William E. Fann, MTP Press Limited, 1980. £20.50 (x + 271 pages) ISBN 0 85200 549 0 (1982) (0)
Acute mood and cognitive effects of a novel herbal extract (ONP-22) in healthy elderly volunteers (2002) (0)
The treatment of visual hallucinations at present and in the future (2014) (0)
Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: Increased alpha 7 immunoreactivity of astrocytes in Alzheimer's disease (2002) (0)
Dementia with Lewy Bodies: Index (1996) (0)
Acetylcholine Esterase and All Elements of the Cholinergic and Monoaminergic Transmitter Signalling Pathways (1997) (0)
16. Dementia with Lewy bodies (2002) (0)
Peptidase activities in Alzheimer's disease (1983) (0)
Alzheimer's and Parkinson's disease: anatomical, pathological and biochemical aspects (1986) (0)
Seeing for ourselves: Insights into the development of moral behaviour from models of visual perception and misperception (2018) (0)
Cholinergic changes in autistic spectrum disorders (2015) (0)
NEUROTRANSMITTERS AD DISEASES OF THE BRAIN (1991) (0)
Cholinergic therapy for symptomatic treatment and disease modification (2002) (0)
Dementia with Lewy Bodies: Foreword (1996) (0)
Symposium of Plant and the Central Nervous System (CNS), September 9: Plants as toxins, tools and therapeutic agents in the CNS (1998) (0)
Nicotine inhibits the release of H3 GABA from rat and human cerebral cortex, in vitro (1990) (0)
HERAPY FOR A UTISTIC S PECTRUM D ISORDERS : R EVIEW AND C ASE R EPORT (2011) (0)
CNS cholinergic markers and Alzheimer's disease (1986) (0)
Contents Vol. 11, 2000 (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Elaine K. Perry?

Elaine K. Perry is affiliated with the following schools:

Newcastle University

Elaine K. Perry's Academic­Influence.com Rankings

Why Is Elaine K. Perry Influential?

Elaine K. Perry's Published Works

Published Works

What Schools Are Affiliated With Elaine K. Perry?

Elaine K. Perry's AcademicInfluence.com Rankings